VBI Looking To Market More Potent, Less Expensive Hepatitis B Vaccine
Executive Summary
Sci-B-Vac was shown more effective at fewer doses than Engerix-B in a Phase III study. VBI Vaccines sees its hepatitis B vaccine hitting potential markets by 2021.
You may also be interested in...
Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.
Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.
Evofem Takes Aim At Preventing Pregnancy And STIs With Amphora
Evofem Biosciences is preparing for Phase III trials for Amphora, an on-demand contraceptive that has surpassed Phase II endpoints in preventing bacterial sexually transmitted infections.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports